Treatment of primary progressive freezing of gait with high doses of selegiline.

abstract：:The long-term effects of mesulergine, a new drug with dopamine agonistic properties, were studied in 28 patients with Parkinson's disease. In 18 patients with late side effects of levodopa, the addition of mesulergine (10.9 mg/day) induced significant decreases in the global (-48%), rigidity (-62%), and akinesia (-37%...

journal_title：Clinical neuropharmacology

authors： Rascol A,Montastruc JL,Rascol O,Senard JM

更新日期：1986-01-01 00:00:00

abstract：OBJECTIVE:A multicenter open-label clinical trial was conducted to evaluate the clinical usefulness of topiramate (TPM) as primary or adjunctive therapy for infantile spasms in the postmarketing period in China. METHODS:Thirty-four centers participated in the trial. Patients included in the study had 1 or more seizure...

journal_title：Clinical neuropharmacology

authors： Zou LP,Lin Q,Qin J,Cai FC,Liu ZS,Mix E,Topiramate Study Group.

更新日期：2008-03-01 00:00:00

abstract：:Daily 20-mg doses of Copolymer 1 have been shown to significantly decrease the relapse rate in patients with multiple sclerosis (MS). In the present open-label study, patients with relapsing MS were treated with the same dose of Copolymer 1 administered on alternate days. Sixty-eight patients were recruited: fifty-one...

journal_title：Clinical neuropharmacology

authors： Flechter S,Kott E,Steiner-Birmanns B,Nisipeanu P,Korczyn AD

更新日期：2002-01-01 00:00:00

abstract：:Apomorphine, the first dopamine agonist to be synthesized, has received a renewed interest in the last few years. This compound acts powerfully on D1 and D2 dopamine receptors and has the most complete pharmacological profile of all clinically available dopamine agonists. When given subcutaneously, apomorphine consist...

journal_title：Clinical neuropharmacology

authors： Colosimo C,Merello M,Albanese A

更新日期：1994-06-01 00:00:00

abstract：:A matter of debate is the impact of levodopa (LD) application in patients with Parkinson disease (PD) on altered force development and coordination, which are also influenced by the strength of muscles used. The objectives were to compare the motor response, the development of grip strength, and the pharmacokinetic be...

journal_title：Clinical neuropharmacology

authors： Müller T,Kolf K,Ander L,Woitalla D,Muhlack S

更新日期：2008-05-01 00:00:00

abstract：OBJECTIVE:The use of amobarbital in the Wada test varied between epilepsy centers, with no unified dosing or protocols available in the literature to standardize its use. We aimed to determine the dose of amobarbital in the presurgical evaluations of patients with temporal lobe epilepsy. METHODS:A retrospective study ...

journal_title：Clinical neuropharmacology

authors： Bajammal S,Babtain F,Alqadi K,Baeesa S,Kurdi K,Madani N,Al Said Y

更新日期：2020-11-01 00:00:00

abstract：OBJECTIVES:To evaluate the clinical outcome of Parkinson disease (PD) patients treated with selegiline (with L-Dopa/decarboxylase inhibitor) in the early stage of the disease in comparison with that of late-stage use of selegiline. METHODS:The study and the reference groups were extracted from a large database of the ...

journal_title：Clinical neuropharmacology

authors： Mizuno Y,Kondo T,Kuno S,Nomoto M,Yanagisawa N

更新日期：2010-01-01 00:00:00

abstract：:Various reactions to benzodiazepine withdrawal have been widely described. Among these, seizures have occasionally occurred on abrupt withdrawal. Our own experience of 48 cases of seizures suspected to have been caused by benzodiazepine withdrawal and reported to the Adverse Drug Reaction (ADR) Monitoring Center (1979...

journal_title：Clinical neuropharmacology

authors： Fialip J,Aumaitre O,Eschalier A,Maradeix B,Dordain G,Lavarenne J

更新日期：1987-12-01 00:00:00

abstract：OBJECTIVE:The aim of this study was to report the case of a male patient with Parkinson disease who developed brachial plexopathy (BP) due to varicella-zoster virus, which was successfully treated with human immunoglobulin. METHOD:We report the case of a 75-year-old male subject with a diagnosis of Parkinson disease w...

journal_title：Clinical neuropharmacology

authors： Sáenz-Farret M,Sandoval-Rodríguez V,Paz-Navarro CE,Zúñiga-Ramírez C

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:Serotonin syndrome (SS) is a potentially life-threatening condition that can be caused by use of proserotonergic drugs. Several studies have reported that combined administration of various medications may induce SS. We report a case of SS in a patient who was being treated with dopaminergic and noradrenergi...

journal_title：Clinical neuropharmacology

authors： Jeon DG,Kim YW,Kim NY,Park JH

更新日期：2017-07-01 00:00:00

abstract：:To evaluate two different dosage regimens for albendazole (7.5 mg/kg twice a day or 5.0 mg/kg three times a day), a study was performed in 10 patients with a diagnosis of parenchymal brain cysticercosis. Each patient received both regimens sequentially according to a randomized, crossover design. Blood and urine sampl...

journal_title：Clinical neuropharmacology

authors： Sánchez M,Suástegui R,González-Esquivel D,Sotelo J,Jung H

更新日期：1993-02-01 00:00:00

abstract：:Levodopa (LD) is one of the most effective drugs for clinical symptoms in patients with Parkinson disease (PD). Most PD patients are advanced in age and may have trouble with LD absorption because aging influences drug absorption processes. Previous reports have indicated that ascorbic acid (AsA) can reduce LD dosage ...

journal_title：Clinical neuropharmacology

authors： Nagayama H,Hamamoto M,Ueda M,Nito C,Yamaguchi H,Katayama Y

更新日期：2004-11-01 00:00:00

abstract：:Adjunctive use of methylphenidate, a central stimulant, has been considered as a potential therapeutic choice for patients with refractory unipolar depression, geriatric depression, bipolar depression, and depression secondary to a medical illness. We present a case of psychotic unipolar depression in which the patien...

journal_title：Clinical neuropharmacology

authors： Huang CC,Shiah IS,Chen HK,Mao WC,Yeh YW

更新日期：2008-07-01 00:00:00

abstract：:In this report, we present a patient whose positive symptoms did not improve despite being treated with clozapine monotherapy at a therapeutic dose for 4 months, and whose symptoms began to resolve after aripiprazole long-acting injection adjunction to clozapine. A 22-year-old man was diagnosed as having schizophrenia...

journal_title：Clinical neuropharmacology

authors： Balcioglu YH,Gokcay H,Yesilkaya UH

更新日期：2020-09-01 00:00:00

abstract：:The results of pharmacokinetic studies of two recent 5-HT uptake inhibitors, zimelidine and fluoxetine, have pointed to the inadequacy of open-dose rising studies for establishing the most appropriate dose of new antidepressants. High plasma concentrations of the active metabolites, norzimelidine and norfluoxetine, we...

journal_title：Clinical neuropharmacology

authors： Montgomery SA,Baldwin D,Shah A,Green M,Fineberg N,Montgomery D

更新日期：1990-01-01 00:00:00

abstract：:Sarcosinemia is a relatively rare autosomal recessive disorder that has a varied phenotypic presentation; rarely, it is associated with neurodevelopmental and neurological abnormalities. Sarcosine is a key intermediate in 1-carbon metabolism, and its elevation in blood and urine could reflect a deficient pool size of ...

journal_title：Clinical neuropharmacology

authors： Deutsch SI,Rosse RB,Long KD,Gaskins B,Mastropaolo J

更新日期：2006-11-01 00:00:00

abstract：:Following oral administration in the fasting healthy subject, the mean maximum concentration of tianeptine is 334 +/- 79 ng/ml. Absorption of tianeptine from the tablet form is rapid and complete. Maximum plasma concentration is obtained by the first hour following administration (0.94 +/- 0.47 h). Absolute bioavailab...

journal_title：Clinical neuropharmacology

authors： Royer RJ,Albin H,Barrucand D,Salvadori-Failler C,Kamoun A

更新日期：1988-01-01 00:00:00

abstract：:Tremors other than those associated with Parkinson's disease are commonly encountered in clinical practice. The differentiation of tremor subtypes depends primarily on the presence of distinct clinical characteristics and is facilitated by the use of consistent nomenclature. Such differentiation can be helpful in dete...

journal_title：Clinical neuropharmacology

authors： O'Sullivan JD,Lees AJ

更新日期：2000-09-01 00:00:00

abstract：:The effects of the psychotropic drug etoperidone on the response to laboratory stressors was investigated in a controlled study. Cardiovascular and hormonal (catecholamines, corticotropin, and cortisol) measurements were made in a group of young, healthy volunteers during a cold pressor test (CPT), a mental arithmetic...

journal_title：Clinical neuropharmacology

authors： Costa A,Martignoni E,Blandini F,Petraglia F,Genazzani AR,Nappi G

更新日期：1993-04-01 00:00:00

abstract：:We investigated genetic polymorphism of the cytochrome P-450 CYP2D6 gene from white patients with idiopathic Parkinson's disease (IPD). The mutations of the CYP2D6 gene associated with the poor metabolizer (PM) phenotype of the debrisoquine/sparteine polymorphism were analyzed in DNA of 130 IPD patients by a polymeras...

journal_title：Clinical neuropharmacology

authors： Bordet R,Broly F,Destée A,Libersa C,Lafitte JJ

更新日期：1996-06-01 00:00:00

abstract：:Glutamine synthetase (GS), an enzyme localized in astroglial cells in the brain, is directly implicated in brain detoxification. An ontogenic study of GS activity was performed in homogenates from four distinct brain areas in comparison with the respective astrocytes obtained in primary cultures. GS was induced by hyd...

journal_title：Clinical neuropharmacology

authors： Tardy M,Rolland B,Fages C,Caldani M

更新日期：1984-01-01 00:00:00

abstract：:The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times dai...

journal_title：Clinical neuropharmacology

authors： Jorga KM,Davis TL,Kurth MC,Saint-Hilaire MH,LeWitt PA,Fotteler B,Zürcher G,Rabbia M

更新日期：2000-03-01 00:00:00

abstract：:In the United States, trazodone has shown efficacy comparable with tricyclic antidepressants. Trazodone's side-effect profile, however, is vastly superior to the older drugs. In cases of overdose, trazodone alone has not caused a single death. For depressed patients, starting with 150 mg/day of trazodone, preferably a...

journal_title：Clinical neuropharmacology

authors： Fabre LF

更新日期：1989-01-01 00:00:00

abstract：OBJECTIVE:Although hormone replacement therapy (HRT) improves menopausal depressive symptoms, women unresponsive to HRT need an antidepressant drug as an effective adjunctive therapy. The aim of this study was to assess whether the herbal medicine Unkei-to has an impact on HRT-resistant menopausal depressive symptoms a...

journal_title：Clinical neuropharmacology

authors： Koike K,Ohno S,Takahashi N,Suzuki N,Nozaki N,Murakami K,Sugiura K,Yamada K,Inoue M

更新日期：2004-07-01 00:00:00

abstract：OBJECTIVES:We investigated the effects of age on the association between early and eventual responses to paroxetine treatment in patients with major depressive disorder (MDD). METHODS:Eighty-nine patients with MDD were administered paroxetine and completed the 6-week protocol. On the basis of our previous study, we de...

journal_title：Clinical neuropharmacology

authors： Tomita T,Sato Y,Nakagami T,Tsuchimine S,Kaneda A,Kaneko S,Nakamura K,Yasui-Furukori N

更新日期：2015-01-01 00:00:00

abstract：:Modafinil is a psychostimulant compound that is just now becoming available in many countries for treatment of narcoleptic and hypersomnic patients. Whereas sleep attacks and drowsiness can be effectively improved, the drug does not sufficiently reduce cataplectic seizures. It therefore is often used in combination wi...

journal_title：Clinical neuropharmacology

authors： Grözinger M,Härtter S,Hiemke C,Griese EU,Röschke J

更新日期：1998-03-01 00:00:00

abstract：:Flumazenil is a benzodiazepine receptor antagonist. It is currently used mainly in the anaesthetic and emergency rooms to reverse the effect of exogenous benzodiazepines. Its use in a variety of experimental animal models and in human neuropsychiatric disorders continues to generate a wealth of information on the poss...

journal_title：Clinical neuropharmacology

authors： Malizia AL,Nutt DJ

更新日期：1995-06-01 00:00:00

abstract：:Monoamine oxidase (MAO) inhibitors (MAOIs) provide effective alternative therapy for those patients with major depression who do not respond to tricyclic antidepressants or such related compounds as the selective serotonin reuptake inhibitors. This article reviews studies on the efficacy of both the classical MAOIs an...

journal_title：Clinical neuropharmacology

authors： Nolen WA,Hoencamp E,Bouvy PF,Haffmans PM

更新日期：1993-01-01 00:00:00

abstract：OBJECTIVES:Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response. METHODS:One hundred thirty...

journal_title：Clinical neuropharmacology

authors： Song J,Kim SW,Hong HJ,Lee MG,Lee BW,Choi TK,Lee SH,Yook KH

更新日期：2014-09-01 00:00:00

abstract：:The main augmentation strategy in the treatment of obsessive-compulsive disorder (OCD) is the addition of low-dose dopamine antagonists, such as risperidone. However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to these strategies. In the present repo...

journal_title：Clinical neuropharmacology

authors： da Rocha FF,Correa H

更新日期：2011-07-01 00:00:00